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Abstract: Poly(ADP-ribosyl)-ation is a nonprotein posttranslational modification of 
proteins and plays an integral part in cell physiology and pathology. The metabolism of 
poly(ADP-ribose) (PAR) is regulated by its synthesis by poly(ADP-ribose) polymerases 
(PARPs) and on the catabolic side by poly(ADP-ribose) glycohydrolase (PARG). PARPs 
convert NAD+ molecules into PAR chains that interact covalently or noncovalently with 
target proteins and thereby modify their structure and functions. PAR synthesis is activated 
when PARP1 and PARP2 bind to DNA breaks and these two enzymes account for almost 
all PAR formation after genotoxic stress. PARG cleaves PAR molecules into free PAR and 
finally ADP-ribose (ADPR) moieties, both acting as messengers in cellular stress 
signaling. In this review, we discuss the potential of RNAi to manipulate the levels of 
PARPs and PARG, and consequently those of PAR and ADPR, and compare the results 
with those obtained after genetic or chemical disruption. 
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1. The Life Cycle of Poly (ADP-Ribose) 
Poly(ADP-ribosyl)-ation belongs to the nonprotein posttranslational modifications and is a 
metabolite of the enzymatic cofactor nicotinamide adenine dinucleotide (NAD+). Poly (ADP-ribose) 
polymerases (PARPs) cleave the nicotinic moiety from NAD+ and convert the ADP-ribose (ADPR) 
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units into long APD-ribose polymers (PAR). At the protein level, the E-D-loop-E-D NAD+ fold is the 
most conserved region in PARPs and is therefore termed the PARP signature motif [1±3]. To date, 17 
distinct PARP enzymes have been discovered and numbered accordingly. Recently a new 
nomenclature has been suggested that is based on their transferase activity (ARTD nomenclature [4]): 
PARP1 (ARTD1), PARP2 (ARTD2), PARP3 (ARTD3), PARP4 (ARTD4, vault-PARP), PARP5A 
(ARTD5, Tankyrase 1), PARP5B (ARTD6, Tankyrase 2), PARP6 (ARTD17), PARP7 (ARTD14, 
TIPARP, RM1), PARP8 (ARTD16), PARP9 (ARTD9, BAL1), PARP10 (ARTD10), PARP11 
(ARTD11), PARP12 (ARTD12, ZH3HDC1), PARP13 (ARTD13, ZC3HAV1, ZAP1), PARP14 
(ARTD8, BAL2 COAST6), PARP15 (ARTD7, BAL3), and PARP16 (ARTD15). However, not all 
PARP enzymes are proven poly(ADP-ribose) polymerases. Several of them seem to belong to the class 
of mono(ADP-ribosyl) transferases [5]. The nuclear PARP1 and PARP2 are the best characterized 
PARPs in mammals and are true poly(ADP-ribose) polymerases. PARP1 has a modular structure  
and starts its catalytic activity after binding to DNA nicks and breaks with the double zinc finger 
domain [2]. Recently, a third zinc finger-like structure was discovered. It is required for transmitting 
DNA-induced conformational changes to the catalytic domain [6,7]. The C-terminal catalytic domain 
sequentially transfers ADPR units from NAD+ to protein acceptors generating PAR. Third, in the 
automodification domain, specific glutamatic acid and lysine residues serve as acceptors of ADPR 
allowing the enzyme to poly(ADP-ribosyl)ate itself. While the level of PAR is very low under 
physiological condition, it rises 200-fold under genotoxic stress conditions. After DNA damage, 
PARP1 is rapidly recruited and its catalytic activity increases 10- to 500-fold to synthesize long and 
branched PAR chains (Figure 1) [3,8]. PARP1 is the main enzyme generating PAR and it is the main 
acceptor for covalent PAR modification. More than 90% of PAR originates from PARP1 during 
genotoxic stress [8,9]. PARP-bound PAR can recruit many other proteins involved in distinct cellular 
functions, including enzymes involved in DNA repair [10±16]. The system of PAR accepting and/or 
interacting proteins is very complex and not completely understood. Moreover, novel proteome-wide 
analyses allow the identification of putative PAR binding proteins [10]. Automodification of PARP1 
diminishes the affinity of the enzyme for DNA breaks. This provides a mechanism for removing 
PARP1 from damaged DNA and for local modulation of chromatin compaction and transcriptional 
regulation [11,17±19]. 
Apart from PARP1, PARP2 is activated by DNA strand breaks, as well [20,21]. The DNA-binding 
domain (DBD) of PARP2 is structurally different from that of PARP1 [20,22]. PARP2 binds less 
efficiently to DNA single-strand breaks (SSB) than PARP1 but it detects gap and flap structures [23]. 
PARP2 consumes less NAD+ compared to PARP1 due to its less efficient PAR synthesis [20]. It 
contributes only 5%±10% of the total PARP activity in response to DNA interruptions [20,24]. 
The enzymatic product of PARP1 and PARP2 activity PAR comprises a heterogeneous pool of 
negatively charged molecules that differ in length and branching. It is noteworthy that the 
hyperactivation of PARP1 and PARP2, due to genotoxic stress, consumes most of the NAD+ in a  
cell [25]. Free or protein-associated PAR, synthesized after a genotoxic insult, are rapidly degraded in 
vivo with a half-life of less than 40 sec, while the residual fraction is catabolized with a half-life of 6 
min [26±28]. The degradation of PAR is catalyzed by PARG (PAR glycohydrolase), an enzyme with 
both endo- and exoglycosidic activities that hydrolyze the glycosidic bond between ADPR units. 
PARG produces primarily monomeric ADPR via exoglycosidic activity, albeit a few free PAR 
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polymers may arise from endoglycosic cleavage (Figure 1) [29,30]. In addition, PARG displays less 
activity towards branched or short PAR (KM § 10 µM) compared with long and linear PAR molecules  
(KM § 0.1±0.4 µM) [29±34]. PARG is encoded by a single gene in mammals, and several splicing 
products are formed after transcription. They are translated into proteins of different molecular size, 
subcellular localization and the ability to cleave PAR. The nuclear mPARG-110/hPARG-111 isoform 
represents the full-length PARG protein in mice and humans and accounts for most of the PARG 
activity [35]. Recently another PAR-degrading enzyme has been described. The ADPR hydrolase 3 
(ARH3) is structurally not related to PARG and is less efficient. Nevertheless, it provides PAR-
degrading activity in vitro and in PAR-enriched mitochondria, as it has been demonstrated in a PARP 
overexpression system [36±38]. 
Figure 1. Poly(ADP-ribose) metabolism. Single-strand and double-strand breaks (SSB and 
DSB) in the DNA are induced by genotoxic stress (1). The nuclear PARPs bind to the 
damaged site and are thereby activated and produce ramified and highly negatively charged 
poly(ADPribose) (PAR) (2). They hydrolyze NAD+, releasing nicotinamide (Nam) and H+, 
catalyzing the successive transfer of ADPR to acceptors (Prot) (3). PARG is the catabolic 
enzyme with endo- and exoglycosidic activity (4). Its hydrolyzing activity leads to either 
free PAR chains (5) and/or monomeric ADPR (6).  
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The two products of PARP/PARG interplay have been identified to exhibit different cellular 
signaling functions. The manipulation of either PARP or PARG activity modifies the occurrence of 
PAR and ADPR after genotoxic stress (Figure 1). This allows the study of distinct PAR and ADPR 
functions. Here, we discuss approaches to interfere with PAR metabolism to clarify the biological role 
of this nonprotein posttranslational modification (PAR) and its degradation product (ADPR). 
2. Experimental Tools to Investigate PAR and ADPR 
2.1. Chemical Inhibition of PAR Metabolizing Enzymes 
Within the last few decades, the concept of interfering with proteins involved in DNA repair and 
stress signaling has attracted a lot of attention in both basic and clinical research. To date, chemical 
inhibitors against PARP enzymes have reached the first level of clinical application. Almost all PARP 
inhibitors in preclinical and clinical studies compete with the substrate NAD+ for the catalytic domain 
leading to a reversible inhibition of enzyme activity. The third generation PARP inhibitors veliparib 
(ABT-888) and olaparib (AZD2281/KU-0059436) are the most clinically investigated, and their  
half-maximal inhibitory concentration (EC50 or Ki) is in the nanomolar range for PARP1 and PARP2 
(Figure 2) [39,40]. Both inhibitors are sufficiently bioavailable when administered orally and they are 
primarily used as anticancer drugs alone or in combination with other treatments (discussed in [41]). 
Moreover, the potential of PARP inhibitors to participate in the concept of synthetic lethality is under 
investigation [41,42]. 
The PARP inhibitors 3-Aminobenzamide (3-AB) [25,43±45], 1,5,7,8-Tetrahydro-2-methyl-4H-
thiopyrano[4,3-d]pyrimidin-4-one (DR2313) [25,46], N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)- 
(N,N-dimethylamino)acetamide (PJ-34) [25,47±50], 8-Hydroxy-2-methylquinazoline-4-one (NU1025) 
[51±53], and 3,4-Dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) [54±57], were 
extensively used to suppress PARP activity in vitro, in cells and animals (Figure 2). They share the 
potential to interfere with both PAR-synthesizing enzymes activated by DNA damage due to the 
homology in the catalytic domain of PARP1 and PARP2, albeit with different kinetics. To overcome 
this problem, Moroni and co-workers developed a set of specific PARP2 inhibitors [58]. Beside 
synthetic PARP inhibitors, a panel of naturally occurring molecules was discovered that have PARP-
suppressing activity. These compounds cover such different chemical structures as tryptophan 
derivatives, purines, xanthins, vitamins, hormones and metals [59]. 
Much less is known about the inhibitors of PARG, as was recently reviewed [60]. Whereas a 
number of natural and synthetic molecules have been described to exhibit PARG-suppressing activity, 
most of them are restricted in terms of bioavailability and/or specificity. Nevertheless,  
the use of Adenosine 5'-diphosphate (hydroxymethyl) pyrrolidinediol (ADP-HPD) [61,62],  
3-Galloyl-Įȕ-D-glucose [63], (Z)-3-(5-(5-Bromo-1-(2,6-dichlorobenzyl)-2-oxoindolin-3-ylidene)-4-oxo-2-
thioxo-thiazolidin-3-yl) propanoic acid [64], and 3,5-Dichloro-N-(3-chloro-4-(naphtalen-2-yloxy)phenyl)-2-
hydroxy benzamide [65] may inhibit PARG specifically and help understand its role within a wider 
biological context (Figure 3). 
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Figure 2. PARP inhibitors.  
 
Drug name IUPAC name IC50/EC50 Reference 
3-AB 3-Aminobenzamide ȝ0(IC50) [43] 
ABT-888 
(Veliparib) 
2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-
carboxamide 
2 nM (EC50)  [40] 
AZD-2281 
(Olaparib) 
4-[(3-[(4-Cyclopropylcarbonyl)piperazin-4-yl] carbonyl)-
4-fluorophenyl]methyl(2H)phthalazin-1-one 
1±5 nM 
(IC50) 
[39] 
DPQ 
3,4-Dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-
isoquinolinone 
40 nM (IC50) [54] 
DR2313 
1,5,7,8-Tetrahydro-2-methyl-4H-thiopyrano[4,3-d] 
pyrimidin-4-one 
ȝ0 (IC50) [46] 
NU1025 8-Hydroxy-2-methylquinazoline-4-one ȝ0(IC50) [51] 
PJ-34 
N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-
dimethylamino)acetamide 
20 nM (EC50)  [49] 
ADP-HPD Adenosine 5'-diphosphate (hydroxymethyl) pyrrolidinediol 0.12  [61] 
Mono-galloyl 
glucose 
3-galloyl-Įȕ-D-glucose 0.95 ± 0.02  [63] 
RBPI-2 
(Z)-3-(5-(5-Bromo-1-(2,6-dichlorobenzyl)-2-oxo-indolin-
3-ylidene)-4-oxo-2-thioxothiazo-lidin-3-yl) propanoic acid 
2.9 ± 1.8  [64] 
Salicylanilide 
3,5-Dichloro-N-(3-chloro-4-(naphtalen-2-yloxy) phenyl)-
2-hydroxybenzamide 
12 ± 2 [65] 
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DPQ 
DR2313 
NU1025 
PJ-34 
AZD-2281 
ABT-888
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Figure 3. PARG inhibitors. 
 
Common Name IUPAC  Name IC50 [µM] Reference 
ADP-HPD Adenosine 5'-diphosphate (hydroxymethyl) 
pyrrolidinediol 
0.12 [61] 
Mono-galloyl glucose 3-galloyl-Įȕ-D-glucose 0.95± 0.02 [63] 
RBPI-2 (Z)-3-(5-(5-Bromo-1-(2,6-dichlorobenzyl)-2-oxo-
indolin-3-ylidene)-4-oxo-2-thioxothiazo-lidin-3-yl) 
propanoic acid 
2.9 ± 1.8 [64] 
Salicylanilide 3,5-Dichloro-N-(3-chloro-4-(naphtalen-2-yloxy) 
phenyl)-2-hydroxybenzamide 
12 ± 2 [65] 
2.2. Genetic Disruption of PARPs and PARG 
In the mid-1990s, the first PARP knock out (k.o.) mice were created to provide more detailed and 
specific information about the physiological role of PARP enzymes in different cellular responses. 
Wang et al. generated in 1995 a PARP1 k.o. mouse line by interrupting exon 2 [66]. The existence of 
these mice suggested initially that PARP1 is dispensable during embryogenesis. These mice were 
fertile, obviously healthy and revealed no dramatic phenotype. However, isolated cells derived from 
Parp1í/í mice had a marginally lower proliferation rate unrelated to DNA damage. Nevertheless, there 
ADP-HPD 
Salicylanilide 
RPBI-2 
Mono-galloyl  
glucose 
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was an unusual and unexpected development of skin hyperplasia in around 1/3 of mice related to 
progressive aging. The observed skin abnormalities included thickening of all layers of the epidermis, 
active proliferation of keratinocytes, development of intracellular edema and an inflammatory  
response [66]. As 70% of these mice remained free of any skin problems, a correlation between this 
phenotype and the absence of PARP1 seemed unlikely. Ménissier de Murcia et al. developed a second 
Parp1í/í mouse strain using a different ablation strategy by interrupting exon 4 [67], which was 
completely free of any skin pathologies as discussed in more detail by Rhun et al. [68]. These PARP1 
k.o. mice exhibited an extreme sensitivity to whole body J-radiation, indicating a functional link 
between PARP1 and DNA stress. This first report was later confirmed by Wang et al. investigating 
their first Parp1í/í mouse type [69]. Additionally, Ménissier de Murcia and colleagues showed that the 
whole body exposure to 8 Gy resulted in a very short half-life of four days with a complete lethality 
after eight days, compared to 50% lethality observed in control mice (14±20 days). Dramatic lethality 
with extensive necrosis occurred in the epithelial lining of the small intestine [67]. Furthermore, high 
sensitivity to intra-peritoneal administration of 75 mg/kg of body weight of the alkylating agent N-
methyl-N-nitrosourea (MNU) was observed. They determined 80% lethality within the first week in 
Parp1í/í mice compared to 40% for control mice until week eight. 
Results obtained in these two different Parp1í/í mice lines demonstrated the involvement of 
PARP1 in processing genotoxic attacks. Both authors concluded that the lack of the Parp1 gene led to 
an impaired DNA repair capacity, an accumulation of DNA strand breaks and, subsequently, high 
genomic instability. The results of the k.o. experiments performed by Wang et al. and Ménissier de 
Murcia et al. are summarized in Table 1. None of the approaches to diminish the Parp1 gene resulted 
in the expression of fully functional truncates. However, Wang et al. reported a truncated 1.2 kb 
transcript generating a PARP1 fragment but without any enzymatic activity. 
In 1999, a partial functional redundancy between PARP1 and PARP2 was observed by Amé et al. [20]. 
As a logical consequence, mice lacking PARP2 were needed. Therefore, Ménissier de Murcia and co-
workers generated the first Parp2í/í mice line by disrupting exon 9 [70]. These manipulated mice were 
fertile and viable like the Parp1í/í mice. Interestingly, they showed an even higher sensitivity to 
genotoxic challenges than their Parp1í/í counterparts. Moreover, Parp2í/í mice displayed 
abnormalities in spermiogenesis caused by delayed nuclear elongation. They developed lipodystrophy 
characterized by adipodegeneration, as well as derailed differentiation of preadipocytes to adipocytes. 
It was also reported that genetic depletion of Parp2í/í resulted in reduced CD4+CD8+ thymocyte 
cellularity, the overexpression of the proapoptotic proteins Noxa and Puma as well as a reduced 
expression of the T-cell receptor (TCR) D [21,71±74]. The importance of the PAR metabolizing 
enzymes PARP1 and PARP2 is further illustrated by the fact that a double k.o. results in embryonic 
death. This can be observed already in the early stage of gastrulation leading to a complete loss of the 
offspring [70,75]. 
After the first demonstration of PARP1 and PARP2 functions using k.o. mice, another breakthrough 
was made by the disruption of the PAR degrading enzyme PARG. First, Koh and colleagues targeted 
exon 4 within the parg gene [76]. This led to early peri-implantation lethality resulting in the failure of 
the embryos to progress and the subsequent degeneration of the blastocyst. However, embryonic 
trophoblast stem cell lines established from early PARG null embryos could be kept viable in culture, 
but only when co-cultured with the traditional PARP inhibitor benzamide (0.5 mM). Moreover, the 
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Pargí/í cells were characterized by reduced growth, an accumulation of PAR and an increased 
sensitivity to the alkylating agent N-methyl-1¶-nitro-N-nitrosoguanidine (MNNG, 20 and 100 PM). An 
improved strategy to impair Parg gene in mice to overcome lethality problems was reported by  
Cortes et al. [77]. They targeted exons 2 and 3 resulting in the depletion of only PARG110 protein 
isoform normally found in the cell nucleus. Due to this elegant approach the mice were viable, fertile 
and phenotypically normal but hypersensitive to alkylating agents (MNU, 150 mg/kg of body weight) 
and ionizing radiation (10 Gy of whole body J-radiation). However, Meyer-Ficca et al. reported a 
reduced number of litters as well as a decreased number of pups per litter in Pargǻí3 mice [78]. 
Moreover, the Pargǻí3 mice were prone to septic shock induced by lipopolysaccharides (LPS, 30 
mg/kg of body weight). Both PARG manipulated mouse models are presented in Table 1.  
2.3. RNA Interference 
Sense RNAs have been typically introduced as negative specificity controls using RNAs 
synthesized in vitro in antisense studies in the 1990s [79]. Interestingly, Guo and Kemphues found that 
control sense as well as antisense RNA molecules resulted in similar phenocopies when administered 
to the worm Caenorhabditis elegans [80]. Further studies in C. elegans revealed that the interfering 
RNA could be transported from the site of initial delivery to most cells and tissues in the worm and 
this systemic response was termed RNA interference or RNAi [81]. Subsequently, it was discovered 
that double-stranded RNA (dsRNA) rather than single-stranded antisense RNA (ssRNA) was 
responsible for the sequence specific degradation of targeted endogenous mRNA in C. elegans [82]. This 
form of posttranscriptional gene silencing in response to transgene sequences was previously 
demonstrated in plants and also in fungi representing an evolutionary well-conserved mechanism. 
Napoli et al. introduced a transgene designed to overexpress chalcone synthase putatively leading to an 
increase in purple pigment production in petunia flowers. Surprisingly, more than 40% of the 
transgenic plants developed white or variegated flowers rather than purple [83]. A similar phenomenon 
of target gene repression in a different model organism was discovered in experiments using the 
fungus Neurosporus crassa [84]. 
Table 1. Murine phenotypes of genetic PARP or PARG disruption. 
Deletion  Phenotype Ref. 
Parp1  Accumulation of DNA strand breaks and impaired DNA repair [66±68] 
   High genomic instability    
   Hypersensitivity to J-irradiation and alkylating agents   
   No defects in viability, fertility, development or tissue differentiation 
Parp2  High genomic instability  [70,73] 
   Hypersensitivity to J-irradiation and alkylating agents   
   Impaired adipogenesis, thymopoiesis, and spermatogenesis   
   No defects in viability, fertility, development or tissue differentiation 
Parp1, Parp2  Embryonic lethality at onset of gastrulation [70,75] 
Parg  Peri-implantation lethality [76] 
Pargǻí3   Increased responses to genotoxic treatment and septic shock [77,78] 
   Phenotypically normal and viable   
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A first mechanistic model resolving this phenomenon originated from comprehensive biochemical 
and genetic studies on flies, worms, fungi, plants, and mammalian cells (Figure 4, reviewed by 
Hutvagner et al. [85]). The RNA-silencing response starts by processing the trigger dsRNA molecules 
into smaller fragments with 21 to 25 ES LQ VL]H WKDW DUH FKDUDFWHUL]HG E\ ¶ GLQXFOHRWLGH RYHUKDQgs. 
The activity of an enzyme called Dicer is required for this process and it depends on adenosine 
triphosphate (ATP). This multidomain protein contains an ATP-dependent RNA helicase, a Piwi 
Argonaut and Zwille (PAZ) domain, two tandem RNase III domains, and a dsRNA-binding domain 
[86]. The final products of the Dicer activity were termed short interfering RNAs (siRNAi) [87]. Each 
siRNA binds subsequently to the RNA-induced silencing complex (RISC) that is composed of 
different protein subunits. In a next step, the siRNAs become unwound due to a helicase component of 
RISC. This allows base pairing between the antisense strand and the target mRNA [88]. 
Endonucleolytic cleavage of the target mRNA via the endonuclease Ago2 leads to fragments missing 
polyA tail or missing 5' 7-Methylguanosine cap leading subsequently to degradation [79]. The 
mechanistic overview is shown in Figure 4. 
To date, four different types of small RNA molecules are described to possess RNA interference. 
(I) Short interfering RNA (siRNA) 
Synthetic siRNA was the first RNAi technology used in mammalian cells for sequence specific 
gene silencing [89]. The siRNA directly incorporates into RISC, where its guide strands binds and 
cleaves the target mRNA. After the release of cleaved mRNA, the guide-strand-bound RISC binds to 
another mRNA starting a new cleavage cycle. siRNAs are capable to cleave and subsequently suppress 
cytoplasmic or nuclear target mRNA [90].  
(II) Short hairpin RNA (shRNA) 
Short hairpin RNA (shRNA) has been developed as an alternative strategy to siRNA and was aimed 
for long-term gene silencing [91,92]. The shRNA is transcribed in the nucleus out of an expression 
vector bearing a short dsDNA sequence with a hairpin loop. The resulting transcript becomes further 
processed after coupling to the cytoplasmic RISC, following the identical fate as described above for 
siRNA. In practice, several aspects of shRNA differ intrinsically from siRNA reviewed by Rao et al. [93]. 
(III) MicroRNA (miRNA) 
MicroRNAs (miRNAs) are highly conserved small noncoding RNAs, which play a role in 
regulating physiological and pathological cell functions. They are initially transcribed in the nucleus as 
primary transcripts from precursors generally located within either intergenic regions or introns of 
protein coding sequences [94]. After processing by an RNAse III endonuclease, the pre-miRNAs are 
exported to the cytoplasm and further cleaved by the Dicer producing 20±23 bp mature miRNAs. The 
miRNAs are subsequently loaded into RISC eliciting transcriptional inhibition with target mRNA 
degradation or sequestration in cytoplasmic P-bodies [95]. Compared to siRNAs and shRNAs, which 
require a perfect match with the target mRNA, miRNAs exert typically translational inhibition by 
binding to a partially complementary mRNA (Figure 4). Therefore, the change in the expression of a 
single miRNA may affect hundreds of different genes [96,97]. 
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(IV) Bi-functional shRNA (bi-shRNA) 
Bi-functional shRNAs (bi-shRNAs) were developed to exploit both the cleavage and translational 
inhibitions mechanisms of RNAi [93]. They consist of two stem-loop shRNAs structures.  
The cleavage-dependent unit perfectly matches passenger and guide-strand, whereas the  
cleavage-independent unit is composed of a mismatched double-strand. Both units are embedded in a 
miR-30 scaffold encoded in a plasmid vector. The mature transcript of the cleavage-dependent part is 
loaded into RISC in complex with the endonuclease Ago2. The processed transcript of the  
cleavage-independent unit functions as a miRNA by binding to RISC inducing mRNA  
degradation/P-body sequestration or transcriptional inhibition. In general, the mechanism of bi-
shRNAs leads to higher efficacy and greater durability compared with siRNA and miRNA [98]. 
The current understanding of therapeutic implementation of all these different small RNA approaches 
has been extensively reviewed: Seyhan discussed the progress and arising challenges in developing 
RNAi therapeutics against genetic diseases [99]. The current status of RNAi-based anticancer therapy 
and their potential clinical application is discussed by Wang et al. [98] and Bora et al. [100]. 
2.4. The Use of RNA Interference against PARP Enzymes 
The possibility to suppress the expression of a specific protein in cell cultures has attracted a lot of 
interest. Moreover, the PAR research was extended to cell systems other than that of murine origin, 
due to RNAi techniques. Historically the first experiments using RNAi as a tool targeting PAR 
metabolism were performed aiming the knock down (k.d.) of PARP1 (Table 2). 
Already in 2002, Gan et al. reported the silencing of PARP1 protein caused by the transfection of 
PARP1-specific dsRNA molecules in murine neuroblastoma cells [101]. They targeted the N- as well 
as the C-terminus of the Parp1 gene, and both approaches diminished the expression of the 
corresponding protein. Further, this study confirmed the resistance of PARP1 abrogated cells to 
oxygen±glucose deprivation as a functional consequence. This phenotype was previously demonstrated 
in cells lacking PARP1 due to genetic ablation. Therefore they suggested the application of RNAi as a 
powerful tool to study gene functions in cells. In 2004, Kameoka et al. introduced RNAi against 
PARP1 in human cell cultures. In this report, the authors studied the HIV-1 replication within HeLa 
and J111 cells that have an impaired PARP1 expression [102]. One of the obvious advantages to prefer 
RNAi rather than chemicals for enzyme inhibition purposes is its specificity. This was demonstrated in 
an elegant study by Shah et al. in 2005 [103]. They developed and compared RNAi approaches 
targeting the C-terminus of the parp1 gene in human, murine and hamster cells and investigated the 
impact of PARP1 k.d. on the expression level of PARP2. As discussed above PARP2 exhibits a 
significant amino acid and nucleotide sequence similarity with PARP1 in the C-terminal domain. The 
RNAi target sequences for PARP1 determined in this study have only three (for the murine) or greater 
than five (hamster, human) mismatches with the parp2 gene. Shah et al. found no impact on PARP2 
expression in the tested PARP1 k.d. models as tested by Western blot analyses. They concluded that 
RNAi against PARP1 does not interfere with its most related protein PARP2 and since other  
PARP-homologs have even greater disparity to PARP2, it is not likely to affect them by RNAi against 
PARP1 [103]. To date, RNAi against PARP1 has been applied to at least 20 different human cell types 
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and to cells derived from other mammalian species (Table 2). These include immortalized, primary 
and cultures from embryonic stem cells. 
Figure 4. The pathway of RNA interference. (a) Highly specific siRNA which are 21±23 
nt double-stranded RNA (dsRNA) duplexes in size with symmetric 2- QXFOHRWLGH ¶
RYHUKDQJVDQG¶SKRVSKDWH3DQG¶K\GUR[\O 2+JURXSV(b) The dsRNA is cleaved 
by Dicer in an ATP-dependent reaction. The siRNAs are subsequently incorporated into a 
multicomponent RNA-inducing silencing complex (RISC). Activated RISC unwinds the 
siRNA in an ATP-dependent fashion. The resulting antisense strand guides the RISC to its 
complementary mRNA before endonucleolytic cleavage of target mRNA. The free ends of 
the mRNA fragments are rapidly degraded by cytoplasmic nucleases. This ultimately 
results in the loss of protein expression. (c) Dicer cleaves the miRNA precursor to produce 
22 nt miRNA. The single-stranded miRNAs are incorporated into RISC, followed by target 
recognition and final translational inhibition [104]. 
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Table 2. RNAi against PARP1 in mammalian cells. Studies labeled with * provide detailed 
targeting sequence information. 
Cell line Cell type Species  References 
293 Embryonic kidney cells Human [105]*, [106,107] 
3T3-L1 Preadipocytes Mouse [108]* 
A20 B-cell lymphoma Mouse [109] 
A549 Lung adenocarcinoma epithelial Human [110,111]*, [107,112±114] 
AGYNB010 Neuroblastoma Mouse [101]* 
bEnd.3 Cerebral vascular endothelial Mouse [114] 
CHO Ovarian cells Chinese hamster [103]* 
EW7 Ewing sarcoma Human [115]* 
GM00637 SV-40 transformed skin fibroblasts Human [116]* 
H9 hESCs Embryonic stem cells Human [117]* 
HaCaT Keratinocytes Human [118,119] 
HCT-116 Colon adenocarcinoma Human [120,121] 
HeLa Cervix carcinoma Human [102,122±128]*, [129,130] 
HepG2 Hepatocytes Human [131] 
HUVEC Endothelial cells Human [132] 
J111 Acute monocytic leukemia Human [102]* 
Jurkat T-cell lymphoma (Type II) Human [133]* 
MCF-7 Breast cancer Human [134]* 
MEF Fibroblasts Mouse [25,103,135,136]* 
NB4 Acute promyelocytic leukemia Human [115]* 
NIT-1 Insulinoma cells Mouse [137]* 
PC12 Prostate cancer Human [138] 
Primary Fibroblasts Human [139]* 
Primary Cerebral cortex neurons Rat [140] 
Primary Rheumatoid arthritis synovial cells Human [141,142] 
Primary Vascular smooth muscle Rat [143] 
Ramos %XUNLWW¶VO\PSKRPD Human [109] 
SHSY5Y Neuroblastoma Human [144] 
SW480 Colorectal adenocarcinoma Human [145] 
WRL-68 Liver cells Human [146] 
RNAi molecules targeting PARP2 were next developed to study distinct and overlapping functions 
of PARP1 and PARP2 in a variety of mammalian cells (Table 3). As described above, PARP2 k.o. has 
created lethality in conjunction with PARP1 k.o. in mice [70]. Here the application of RNAi 
techniques helped to overcome this problem. Within the last years we have investigated the 
combination of either double RNAi (PARP1 and PARP2) in human cells [122,127] or the combination 
of genetic ablation of parp1 gene together with RNAi against PARP2 in murine cell cultures [135]. 
None of the tested systems revealed a lethal phenotype and the cells kept the ability to attach and 
proliferate under normal culture conditions. Woodhouse et al. silenced PARP1 and PARP2 alone or  
in combination in cell cultures derived from primary human fibroblasts and no toxicity was reported  
due to double silencing [139]. This putative discrepancy compared to the Parp1í/í Parp2í/í  
mouse models is most likely related to the noncomplete gene disruption mediated by RNAi in all 
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studies [122,135,139,145]. However, here the implication of RNAi provides advantages to study 
distinct functions of closely related proteins and overcomes lethality problems and the lack of specific 
inhibitors. Whereas PARP1 and PARP2 are the most studied members of the PARP enzyme family, 
RNAi was used as a tool to suppress other PARP enzymes including PARP3 [126,147,148], PARP4 
(vault-PARP) [126], PARP5A (Tankyrase 1) [126,149], PARP5B (Tankyrase 2) [126], PARP7 
(TIPARP) [150] and PARP16 [151]. 
Table 3. RNAi against PARP2 in mammalian cells. Studies labeled with * provide detailed 
targeting sequence information. 
Cell line Cell type Species  References 
293 Embryonic kidney cells Human [72]*, [152] 
A549 Lung adenocarcinoma epithelial Human [111] 
BHK Baby hamster kidney fibroblast Chinese hamster [152] 
C2C12 Myoblasts Mouse [153]* 
HeLa Cervix carcinoma Human [122,126,127]* 
MEF Fibroblasts Mouse [135]* 
MOVAS Aortic smooth muscle Mouse [154]* 
SW480 Colorectal adenocarcinoma Human [145] 
Moreover, RNAi approaches aiming at the organismic level of invertebrates, mice and plants have 
been performed to clarify PAR metabolism in vivo and/or to investigate a possible clinical application 
of RNAi itself. Gravel et al. published in 2004 RNAi experiments targeting the human tankyrase 
related gene pme-5 in the invertebrate C. elegans [155]. The same group demonstrated later the 
effective application of RNAi against the C. elegans PARGs pme-3 and pme-4 [156]. The group of 
Tulin studied PAR metabolism in flies (Drosophila melanogaster). They established and investigated 
RNAi approaches against PARP1 and its counterpart PARG and clarified their involvement in gene 
expression [157,158].  
Popoff et al. investigated antisense oligonucleotides targeting PARP2 in a colitis mouse  
model [159]. Recently, Goldberg and co-workers established whole body silencing of PARP1 studying 
nanoparticle-mediated siRNA delivery in mice [160]. In this analysis, they investigated the tumor 
dissemination in a Brca1-deficient genetic background after application of siRNAs targeting PARP1. 
The stress tolerance of PARP1 and PARP2 impaired Arabidopsis thaliana as well as oilseed rape 
(Brassica napus) plants have been determined using RNAi tools [161,162].  
2.5. The Use of RNA Interference against PARG 
The lack of specific chemical inhibitors and the drastic lethal phenotype of Pargí/í cells as 
discussed above evolved into a set of studies using RNAi to suppress PARG in cells (Table 4). We 
reported previously that silencing of the parg gene in murine and human cells lead to an accumulation 
of PAR after oxidative and alkylating DNA insults [122,163]. The delayed degradation of PAR 
molecules had a protective effect in particular when cells were challenged with the oxidant hydrogen 
peroxide (H2O2). Recently, Feng et al. confirmed this finding in human breast cancer cells treated with 
alkylating agents [164]. Interestingly, the investigation of PARG silencing in mammalian cells after 
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genotoxic challenge has resulted in a hypersensitivity phenotype, as well [111,165,166]. In these 
studies, cells treated with siRNA targeting PARG forced cell death due to PAR accumulation, similar 
to results obtained in cells with a genetic PARG impairment [76]. Andrabi et al. showed that 
artificially introduced PAR molecules trigger an apoptosis inducing factor (AIF) mediated cell death 
pathway [165]. By contrast, an increase of cytoplasmic Ca2+ independent from PARP activity has been 
implicated in the release of AIF from mitochondria subsequently leading to cell death [167]. We 
followed this hypothesis and found that the inhibition of PARG using RNAi diminishes the occurrence 
of free ADPR molecules that can trigger a rise in cytosolic Ca2+ via the transient receptor potential 
mediated channels 2 (TRPM2) [25]. As a consequence, AIF translocation²indicative of cell death²
was abrogated. To date, this Ca2+ channel is the only one activated by monomeric ADPR, and it is 
dependent on PARP/PARG activity [25,168±171]. This finding resolves a long lasting controversy 
about the roles of PAR and ADPR as cell death signals. 
Table 4. RNAi against PARG in mammalian cells. Studies labeled with * provide detailed 
targeting sequence information. 
Cell line Cell type Species References 
16HBE Bronchial epithelial Human [172]* 
293 Embryonic kidney cells Human [107] 
A549 Lung adenocarcinoma epithelial Human [111]*, [107] 
HeLa Cervix carcinoma Human [122,163,165,166,173]* 
LoVo Colon carcinoma Human [174,175]* 
MCF-7 Breast cancer Human [134,163,164]*, [176] 
MEF Fibroblasts Mouse [25,38,163]* 
Primary Rheumatoid arthritis synovial cells Human [142] 
Primary Glioblastoma Human [177]* 
RAW 264.7 Macrophages Mouse [178]* 
3. Conclusions 
The implementation of RNAi has markedly expanded our knowledge of the PAR metabolizing 
system. It has helped to demonstrate distinct functions attributable to PARP members and PARG in a 
nonmurine background. Moreover RNAi helped overcome lethality problems in mice that were 
discovered when PARP1 and PARP2 were ablated simultaneously or when the parg gene was 
depleted. The targeting specificity of the RNAi approach is considerably better than chemical 
inhibitors, which often do not distinguish between individual PARP members or fail to inhibit at all in 
a cellular context because of bioavailability problems (PARG). 
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